Nanoparticles encapsulated with LL37 and serpin A1 promotes wound healing and synergistically enhances antibacterial activity

Molecular Pharmaceutics

Volumn 13, Issue 7, 2016, Pages 2318-2331

  Fumakia, Miral ^a   Ho, Emmanuel A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

anti inflammatory; antibacterial; chronic wounds; combination nanomedicine; drug delivery; LL37; serpin A1; solid lipid nanoparticles; synergy; wound healing

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; COLLAGEN TYPE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; SERINE PROTEINASE INHIBITOR; SERPIN A1; SOLID LIPID NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ALPHA 1 ANTITRYPSIN; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CATHELICIDIN; LIPID; NANOPARTICLE;

ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIUM CONTAMINATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ESCHERICHIA COLI; EX VIVO STUDY; FEMALE; FIBROBLAST; IN VITRO STUDY; KERATINOCYTE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SUSTAINED RELEASE FORMULATION; WOUND CLOSURE; WOUND HEALING; ANIMAL; BACTERIAL INFECTIONS; CELL LINE; CHEMISTRY; DRUG EFFECTS; HUMAN; LEPORIDAE; MEDICINAL CHEMISTRY; NANOMEDICINE; PROCEDURES; SKIN;

ALPHA 1-ANTITRYPSIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BACTERIAL INFECTIONS; CATHELICIDINS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; ESCHERICHIA COLI; FEMALE; FIBROBLASTS; HUMANS; KERATINOCYTES; LIPIDS; NANOMEDICINE; NANOPARTICLES; RABBITS; SKIN; STAPHYLOCOCCUS AUREUS; WOUND HEALING;

EID: 84979085612     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.6b00099     Document Type: Article

References (80)

1. Hurd, T.; Posnett, J. Point prevalence of wounds in a sample of acute hospitals in Canada Int. Wound J. 2009, 6 (4) 287-93 10.1111/j.1742-481X.2009.00615.x
2. Moore, K. Cell biology of chronic wounds: the role of inflammation J. Wound Care 1999, 8 (7) 345-8
3. Bjarnsholt, T.; Kirketerp-Moller, K.; Jensen, P. O.; Madsen, K. G.; Phipps, R.; Krogfelt, K.; Hoiby, N.; Givskov, M. Why chronic wounds will not heal: a novel hypothesis Wound Repair Regen 2008, 16 (1) 2-10 10.1111/j.1524-475X.2007.00283.x
4. Chen, S. M.; Ward, S. I.; Olutoye, O. O.; Diegelmann, R. F.; Kelman Cohen, I. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors Wound Repair Regen 1997, 5 (1) 23-32 10.1046/j.1524-475X.1997.50108.x
5. Rao, C. N.; Ladin, D. A.; Liu, Y. Y.; Chilukuri, K.; Hou, Z. Z.; Woodley, D. T. Alpha 1-antitrypsin is degraded and non-functional in chronic wounds but intact and functional in acute wounds: the inhibitor protects fibronectin from degradation by chronic wound fluid enzymes J. Invest. Dermatol. 1995, 105 (4) 572-8 10.1111/1523-1747.ep12323503
6. Grinnell, F.; Zhu, M. Identification of neutrophil elastase as the proteinase in burn wound fluid responsible for degradation of fibronectin J. Invest. Dermatol. 1994, 103 (2) 155-61 10.1111/1523-1747.ep12392625
7. Huntington, J. A.; Read, R. J.; Carrell, R. W. Structure of a serpin-protease complex shows inhibition by deformation Nature 2000, 407 (6806) 923-6 10.1038/35038119
8. Lomas, D. A. New insights into the structural basis of alpha 1-antitrypsin deficiency QJM 1996, 89 (11) 807-12 10.1093/qjmed/89.11.807
9. Frohm, M.; Gunne, H.; Bergman, A. C.; Agerberth, B.; Bergman, T.; Boman, A.; Liden, S.; Jornvall, H.; Boman, H. G. Biochemical and antibacterial analysis of human wound and blister fluid Eur. J. Biochem. 1996, 237 (1) 86-92 10.1111/j.1432-1033.1996.0086n.x
10. Frohm, M.; Agerberth, B.; Ahangari, G.; Stahle-Backdahl, M.; Liden, S.; Wigzell, H.; Gudmundsson, G. H. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders J. Biol. Chem. 1997, 272 (24) 15258-63 10.1074/jbc.272.24.15258
11. Vandamme, D.; Landuyt, B.; Luyten, W.; Schoofs, L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide Cell. Immunol. 2012, 280 (1) 22-35 10.1016/j.cellimm.2012.11.009
12. Wysocki, A. B.; Staiano-Coico, L.; Grinnell, F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9 J. Invest. Dermatol. 1993, 101 (1) 64-8 10.1111/1523-1747.ep12359590
13. Steinstraesser, L.; Koehler, T.; Jacobsen, F.; Daigeler, A.; Goertz, O.; Langer, S.; Kesting, M.; Steinau, H.; Eriksson, E.; Hirsch, T. Host defense peptides in wound healing Mol. Med. 2008, 14 (7-8) 528-37
14. Heilborn, J. D.; Nilsson, M. F.; Kratz, G.; Weber, G.; Sorensen, O.; Borregaard, N.; Stahle-Backdahl, M. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium J. Invest. Dermatol. 2003, 120 (3) 379-89 10.1046/j.1523-1747.2003.12069.x
15. Shaykhiev, R.; Beisswenger, C.; Kandler, K.; Senske, J.; Puchner, A.; Damm, T.; Behr, J.; Bals, R. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure Am. J. Physiol Lung Cell Mol. Physiol 2005, 289 (5) L842-8 10.1152/ajplung.00286.2004
16. Tokumaru, S.; Sayama, K.; Shirakata, Y.; Komatsuzawa, H.; Ouhara, K.; Hanakawa, Y.; Yahata, Y.; Dai, X.; Tohyama, M.; Nagai, H.; Yang, L.; Higashiyama, S.; Yoshimura, A.; Sugai, M.; Hashimoto, K. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37 J. Immunol. 2005, 175 (7) 4662-8 10.4049/jimmunol.175.7.4662
17. van der Does, A. M.; Bergm, P.; Agerberth, B.; Lindbom, L. Induction of the human cathelicidin LL-37 as a novel treatment against bacterial infections J. Leukocyte Biol. 2012, 92 (4) 735-42 10.1189/jlb.0412178
18. Park, S. C.; Park, Y.; Hahm, K. S. The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation Int. J. Mol. Sci. 2011, 12 (9) 5971-92 10.3390/ijms12095971
19. Haisma, E. M.; de Breij, A.; Chan, H.; van Dissel, J. T.; Drijfhout, J. W.; Hiemstra, P. S.; El Ghalbzouri, A.; Nibbering, P. H. LL-37-derived peptides eradicate multidrug-resistant Staphylococcus aureus from thermally wounded human skin equivalents Antimicrob. Agents Chemother. 2014, 58 (8) 4411-9 10.1128/AAC.02554-14
20. Vermeulen, H.; van Hattem, J. M.; Storm-Versloot, M. N.; Ubbink, D. T. Topical silver for treating infected wounds Cochrane Database Syst. Rev. 2007, 1) CD005486 10.1002/14651858.CD005486.pub2
21. Eltzschig, H. K.; Collard, C. D. Vascular ischaemia and reperfusion injury Br Med. Bull. 2004, 70, 71-86 10.1093/bmb/ldh025
22. Phillips, E.; Young, T. Methicillin-resistant Staphylococcus aureus and wound management Br J. Nurs 1995, 4 (22) 1345-9 10.12968/bjon.1995.4.22.1345
23. Dunford, C. E. Methicillin resistant Staphylococcus aureus Nurs Stand 1997, 11 (25) 58
24. Kauffman, C. A.; Terpenning, M. S.; He, X.; Zarins, L. T.; Ramsey, M. A.; Jorgensen, K. A.; Sottile, W. S.; Bradley, S. F. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment Am. J. Med. 1993, 94 (4) 371-8 10.1016/0002-9343(93)90147-H
25. Mustoe, T. A.; O'Shaughnessy, K.; Kloeters, O. Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis Plast Reconstr Surg 2006, 117, 35S-41S 10.1097/01.prs.0000225431.63010.1b
26. Menke, N. B.; Ward, K. R.; Witten, T. M.; Bonchev, D. G.; Diegelmann, R. F. Impaired wound healing Clin Dermatol 2007, 25 (1) 19-25 10.1016/j.clindermatol.2006.12.005
27. Chen, Y.; Yang, S.; Ho, E. A. Development of an Analytical Method for the Rapid Quantitation of Peptides Used in Microbicide Formulations Chromatographia 2014, 77 (23-24) 1713-1720 10.1007/s10337-014-2777-7
28. Hu, F. Q.; Yuan, H.; Zhang, H. H.; Fang, M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization Int. J. Pharm. 2002, 239 (1-2) 121-8 10.1016/S0378-5173(02)00081-9
29. Trotta, M.; Debernardi, F.; Caputo, O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique Int. J. Pharm. 2003, 257 (1-2) 153-60 10.1016/S0378-5173(03)00135-2
30. Lutz, J. B.; Zehrer, C. L.; Solfest, S. E.; Walters, S. A. A new in vivo test method to compare wound dressing fluid handling characteristics and wear time Ostomy Wound Management 2011, 57 (8) 28-36
31. Chiang, A.; Tudela, E.; Maibach, H. I. Percutaneous absorption in diseased skin: an overview J. Appl. Toxicol. 2012, 32 (8) 537-63 10.1002/jat.1773
32. Blanco, M. D.; Bernardo, M. V.; Teijon, C.; Sastre, R. L.; Teijon, J. M. Transdermal application of bupivacaine-loaded poly(acrylamide(A)-co-monomethyl itaconate) hydrogels Int. J. Pharm. 2003, 255 (1-2) 99-107 10.1016/S0378-5173(03)00036-X
33. Horrevorts, A. M.; de Ridder, C. M.; Poot, M. C.; de Jonge, M. J.; Degener, J. E.; Dzoljic-Danilovic, G.; Michel, M. F.; Kerrebijn, K. F. Chequerboard titrations: the influence of the composition of serial dilutions of antibiotics on the fractional inhibitory concentration index and fractional bactericidal concentration index J. Antimicrob. Chemother. 1987, 19 (1) 119-25 10.1093/jac/19.1.119
34. Liang, C. C.; Park, A. Y.; Guan, J. L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro Nat. Protoc. 2007, 2 (2) 329-33 10.1038/nprot.2007.30
35. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 2010, 70 (2) 440-6 10.1158/0008-5472.CAN-09-1947
36. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev. 2006, 58 (3) 621-81 10.1124/pr.58.3.10
37. Nguyen, D. T.; Orgill, D. P.; Murphy, G. F. Biomaterials for treating skin loss 2009, 25 10.1533/9781845695545.1.25
38. Haake AR, H. K. Biology of Skin. The Parthenon Publishing Group Inc: New York, 2001; p 432.
39. Sams, W. M. Structure and Function of the Skin. In Principles and Practice of Dermatology; Churchill Livingstone, 1990
40. Hu, F. Q.; Hong, Y.; Yuan, H. Preparation and characterization of solid lipid nanoparticles containing peptide Int. J. Pharm. 2004, 273 (1-2) 29-35 10.1016/j.ijpharm.2003.12.016
41. Hayakawa, T.; Kawamura, M.; Okamoto, M.; Baba, M.; Niikawa, T.; Takehara, S.; Serizawa, T.; Akashi, M. Concanavalin A-immobilized polystyrene nanospheres capture HIV-1 virions and gp120: potential approach towards prevention of viral transmission J. Med. Virol. 1998, 56 (4) 327-31 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
42. Schwarz, C.; Mehnert, W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization J. Microencapsulation 1999, 16 (2) 205-13 10.1080/026520499289185
43. Cavalli, R.; Caputo, O.; Marengo, E.; Pattarino, F.; Gasco, M. R. The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a series of model molecules Pharmazie 1998, 53, 392-396
44. Falanga, V. Growth factors and chronic wounds: the need to understand the microenvironment J. Dermatol. 1992, 19 (11) 667-72 10.1111/j.1346-8138.1992.tb03756.x
45. Muller, R. H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art Eur. J. Pharm. Biopharm. 2000, 50 (1) 161-77 10.1016/S0939-6411(00)00087-4
46. Ebrahimi, H. A.; Javadzadeh, Y.; Hamidi, M.; Jalali, M. Repaglinide-loaded solid lipid nanoparticles: effect of using different surfactants/stabilizers on physicochemical properties of nanoparticles Daru, J. Pharm. Sci. 2015, 23 (1) 46 10.1186/s40199-015-0128-3
47. Muller, R. H.; Keck, C. M. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles J. Biotechnol. 2004, 113 (1-3) 151-70 10.1016/j.jbiotec.2004.06.007
48. Liu, J.; Gong, T.; Wang, C.; Zhong, Z.; Zhang, Z. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization Int. J. Pharm. 2007, 340 (1-2) 153-62 10.1016/j.ijpharm.2007.03.009
49. Freitas, C. Stability determination of solid lipid nanoparticles (SLN TM) in aqueous dispersion after addition of electrolyte J. Microencapsulation 1999, 16 (1) 59-71 10.1080/026520499289310
50. Muller, R. H.; Ruhl, D.; Runge, S. A. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time Int. J. Pharm. 1996, 144, 115-121 10.1016/S0378-5173(96)04731-X
51. Olbrich, O.; Muller, R. H. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures Int. J. Pharm. 1999, 180 (1) 31-39 10.1016/S0378-5173(98)00404-9
52. Olbrich, C.; Kayser, O.; Muller, R. H. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)-effect of surfactants, storage time and crystallinity Int. J. Pharm. 2002, 237, 119-128 10.1016/S0378-5173(02)00035-2
53. Scholer, N.; Hahn, H.; Muller, R. H.; Liesenfeld, O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages Int. J. Pharm. 2002, 231 (2) 167-76 10.1016/S0378-5173(01)00882-1
54. Nicoli, S.; Cappellazzi, M.; Colombo, P.; Santi, P. Characterization of the permselective properties of rabbit skin during transdermal iontophoresis J. Pharm. Sci. 2003, 92 (7) 1482-8 10.1002/jps.10405
55. Nicoli, S.; Padula, C.; Aversa, V.; Vietti, B.; Wertz, P. W.; Millet, A.; Falson, F.; Govoni, P.; Santi, P. Characterization of rabbit ear skin as a skin model for in vitro transdermal permeation experiments: histology, lipid composition and permeability Skin Pharmacol Physiol 2008, 21 (4) 218-26 10.1159/000135638
56. Almeida, A. J.; Rainer, S. R.; Muller, H. Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parameters Int. J. Pharm. 1997, 149 (2) 255-265 10.1016/S0378-5173(97)04885-0
57. Almeida, A. J.; Souto, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins Adv. Drug Delivery Rev. 2007, 59 (6) 478-90 10.1016/j.addr.2007.04.007
58. Puglia, C.; Filosa, R.; Peduto, A.; de Caprariis, P.; Rizza, L.; Bonina, F.; Blasi, P. Evaluation of alternative strategies to optimize ketorolac transdermal delivery AAPS PharmSciTech 2006, 7 (3) 61 10.1208/pt070364
59. Jain, S.; Jain, S.; Khare, P.; Gulbake, A.; Bansal, D.; Jain, S. K. Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent Drug Delivery 2010, 17 (6) 443-51 10.3109/10717544.2010.483252
60. Chen, X.; Niyonsaba, F.; Ushio, H.; Okuda, D.; Nagaoka, I.; Ikeda, S.; Okumura, K.; Ogawa, H. Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli J. Dermatol. Sci. 2005, 40 (2) 123-32 10.1016/j.jdermsci.2005.03.014
61. Ong, P. Y.; Ohtake, T.; Brandt, C.; Strickland, I.; Boguniewicz, M.; Ganz, T.; Gallo, R. L.; Leung, D. Y. Endogenous antimicrobial peptides and skin infections in atopic dermatitis N. Engl. J. Med. 2002, 347 (15) 1151-60 10.1056/NEJMoa021481
62. Durr, U. H.; Sudheendra, U. S.; Ramamoorthy, A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides Biochim. Biophys. Acta, Biomembr. 2006, 1758 (9) 1408-25 10.1016/j.bbamem.2006.03.030
63. De, Y.; Chen, Q.; Schmidt, A. P.; Anderson, G. M.; Wang, J. M.; Wooters, J.; Oppenheim, J. J.; Chertov, O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells J. Exp. Med. 2000, 192 (7) 1069-74 10.1084/jem.192.7.1069
64. Porat, R.; Clark, B. D.; Wolff, S. M.; Dinarello, C. A. Enhancement of growth of virulent strains of Escherichia coli by interleukin-1 Science 1991, 254 (5030) 430-2 10.1126/science.1833820
65. Forney, J. R.; Yang, S.; Healey, M. C. Synergistic anticryptosporidial potential of the combination alpha-1-antitrypsin and paromomycin Antimicrob. Agents Chemother. 1997, 41 (9) 2006-8
66. Miyamoto, Y.; Akaike, T.; Alam, M. S.; Inoue, K.; Hamamoto, T.; Ikebe, N.; Yoshitake, J.; Okamoto, T.; Maeda, H. Novel functions of human alpha(1)-protease inhibitor after S-nitrosylation: inhibition of cysteine protease and antibacterial activity Biochem. Biophys. Res. Commun. 2000, 267 (3) 918-23 10.1006/bbrc.1999.2046
67. Ramos, R.; Silva, J. P.; Rodrigues, A. C.; Costa, R.; Guardao, L.; Schmitt, F.; Soares, R.; Vilanova, M.; Domingues, L.; Gama, M. Wound healing activity of the human antimicrobial peptide LL37 Peptides 2011, 32 (7) 1469-76 10.1016/j.peptides.2011.06.005
68. Carretero, M.; Escamez, M. J.; Garcia, M.; Duarte, B.; Holguin, A.; Retamosa, L.; Jorcano, J. L.; Rio, M. D.; Larcher, F. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37 J. Invest. Dermatol. 2008, 128 (1) 223-36 10.1038/sj.jid.5701043
69. Congote, L. F.; Temmel, N.; Sadvakassova, G.; Dobocan, M. C. Comparison of the effects of serpin A1, a recombinant serpin A1-IGF chimera and serpin A1 C-terminal peptide on wound healing Peptides 2008, 29 (1) 39-46 10.1016/j.peptides.2007.10.011
70. Golec, M. Cathelicidin LL-37: LPS-neutralizing, pleiotropic peptide Ann. Agric Environ. Med. 2007, 14 (1) 1-4
71. Rosenfeld, Y.; Papo, N.; Shai, Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action J. Biol. Chem. 2006, 281 (3) 1636-43 10.1074/jbc.M504327200
72. Larrick, J. W.; Hirata, M.; Balint, R. F.; Lee, J.; Zhong, J.; Wright, S. C. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein Infect. Immun. 1995, 63 (4) 1291-7
73. Mookherjee, N.; Brown, K. L.; Bowdish, D. M.; Doria, S.; Falsafi, R.; Hokamp, K.; Roche, F. M.; Mu, R.; Doho, G. H.; Pistolic, J.; Powers, J. P.; Bryan, J.; Brinkman, F. S.; Hancock, R. E. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37 J. Immunol. 2006, 176 (4) 2455-64 10.4049/jimmunol.176.4.2455
74. Subramaniyam, D.; Glader, P.; von Wachenfeldt, K.; Burneckiene, J.; Stevens, T.; Janciauskiene, S. C-36 peptide, a degradation product of alpha1-antitrypsin, modulates human monocyte activation through LPS signaling pathways Int. J. Biochem. Cell Biol. 2006, 38 (4) 563-75 10.1016/j.biocel.2005.09.021
75. Larsen, C. G.; Anderson, A. O.; Oppenheim, J. J.; Matsushima, K. Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor Immunology 1989, 68 (1) 31-6
76. Grimble, R. F. Nutritional antioxidants and the modulation of inflammation: theory and practice New Horiz 1994, 2 (2) 175-85
77. Conner, E. M.; Grisham, M. B. Inflammation, free radicals, and antioxidants Nutrition 1996, 12 (4) 274-7 10.1016/S0899-9007(96)00000-8
78. Lynch, J. P., 3rd; Toews, G. B. Tumor necrosis factor-alpha. A multifaceted mediator of inflammation Chest 1989, 96 (3) 457-9 10.1378/chest.96.3.457
79. Ren, K.; Torres, R. Role of interleukin-1beta during pain and inflammation Brain Res. Rev. 2009, 60 (1) 57-64 10.1016/j.brainresrev.2008.12.020
80. Feghali, C. A.; Wright, T. M. Cytokines in acute and chronic inflammation Front. Biosci., Landmark Ed. 1997, 2, d12-26 10.2741/A171